Program
Telmisartan
Also written as “telmisartan”, “CKD-828, D097, D337” and “Telmisartan 40 mg”.
Its studies are mostly in Hypertension · Essential Hypertension · Diabetic Nephropathies · Hypercholesterolemia · Hyperlipidemias, led by 15 companies.
Drug pageTelmisartan: every studyMany companies study it; this page follows only the 130 they lead. All 177 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 900 open or running | phase 4since May 2, 2002 | May 2, 2002 | none ahead |
| Chong Kun Dang Pharmaceuticalits history only | 122 open or running | phase 4since Mar 9, 2023 | May 20, 2010 | none ahead |
| Yuhanits history only | 81 open or running | phase 4since Nov 10, 2016 | May 29, 2014 | none ahead |
| IlDong Pharmaceuticalits history only | 40 open or running | phase 3since Mar 5, 2014 | Mar 5, 2014 | none ahead |
| Jeil Pharmaceuticalits history only | 30 open or running | phase 3since Mar 8, 2017 | Mar 9, 2015 | none ahead |
| Daewon Pharmaceuticalits history only | 20 open or running | phase 3since Oct 12, 2016 | Oct 12, 2016 | none ahead |
| George Medicines PTYits history only | 20 open or running | phase 3since Aug 15, 2020 | Aug 15, 2020 | none ahead |
| HK inno.Nits history only | 20 open or running | phase 1since Aug 25, 2021 | Aug 25, 2021 | none ahead |
| Daewoong Pharmaceuticalits history only | 10 open or running | phase 1since Mar 4, 2013 | Mar 4, 2013 | none ahead |
| DongKoo Bio & Pharmaits history only | 10 open or running | phase 1since Feb 8, 2018 | Feb 8, 2018 | none ahead |
| Hanlim Pharm.its history only | 10 open or running | phase 3since Dec 2, 2020 | Dec 2, 2020 | none ahead |
| Huons Globalits history only | 11 open or running | phase 1since Aug 5, 2026 | Aug 5, 2026 | Apr 2027phase 1 · NCT07784608 |
| Pharmtechnologyits history only | 10 open or running | phase 1since Oct 8, 2018 | Oct 8, 2018 | none ahead |
| Samil Pharmaceuticalits history only | 10 open or running | phase 1since Oct 13, 2015 | Oct 13, 2015 | none ahead |
| THPharmits history only | 10 open or running | phase 1since Sep 8, 2023 | Sep 8, 2023 | none ahead |
Also a collaborator on its studies: Linical Korea, GlaxoSmithKline and Bayer.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Boehringer Ingelheim only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 7 studies since Mar 11, 2009.
- Jan 28, 2011Phase 3 study in HypertensionNCT01286558 · 225 enrolled · Japan
- Apr 26, 2011Phase 1 study in HealthyNCT01344629 · 64 enrolled · Japan
- Jun 20, 20143 phase 4 studies in HypertensionNCT02172586, NCT02177461, NCT02178306
- Jun 25, 20149 phase 3 studies in HypertensionNCT02175355, NCT02177500, NCT02177487 and 6 more
- Jul 7, 20142 phase 3 studies in HypertensionNCT02183701, NCT02206659
- Jul 7, 20145 phase 1 studies in HealthyNCT02183675, NCT02187536, NCT02187523 and 2 more
- Jul 9, 20142 phase 2 studies in HypertensionNCT02187497, NCT02187484
- Jul 24, 20142 phase 4 studies in HypertensionNCT02200653, NCT02200640
- Aug 12, 20144 phase 1 studies in HealthyNCT02215005, NCT02214992, NCT02214979 and 1 more
- Sep 16, 20143 phase 4 studies in HypertensionNCT02242812, NCT02242370, NCT02242318
- Sep 16, 2014Phase 2 study in HypertensionNCT02242344 · 77 enrolled
- Oct 6, 201417 phase 1 studies in HealthyNCT02259829, NCT02259816, NCT02259803 and 14 more
- Oct 8, 20142 phase 4 studiesNCT02260089, NCT02261116
- Oct 20, 2014Phase 3 study in HypertensionNCT02269176 · 330 enrolled
TargetBeta
“Type-1 angiotensin II receptor antagonist”ChEMBL 37, by rule
Other programs on AGTR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Valsartanrule | Novartis | phase 4 | 145 |
| Losartanrule | Organon | phase 4 | 58 |
| azilsartan medoxomilrule | Takeda | phase 4 | 25 |
| sparsentanrule | travere-therapeutics-inc | phase 4 | 9 |
Studies
The newest 60 of 90 Boehringer Ingelheim leads. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02276391Healthy | 1 | Completed | Oct 2008 | 64 |
| NCT02269176Hypertension | 3 | Completed | Jan 2001 | 330 |
| NCT02263989Healthy | 1 | Completed | Apr 2007 | 30 |
| NCT02262858Healthy | 1 | Completed | Oct 2005 | 68 |
| NCT02262793Healthy | 1 | Completed | Jul 2004 | 24 |
| NCT02262780Healthy | 1 | Completed | Feb 15, 2004 | 20 |
| NCT02262650Healthy | 1 | Completed | May 2004 | 24 |
| NCT02262624Healthy | 1 | Completed | Feb 2005 | 36 |
| NCT02262598Healthy | 1 | Completed | Oct 2004 | 30 |
| NCT02262585Healthy | 1 | Completed | Aug 2002 | 30 |
| NCT02262572Healthy | 1 | Completed | Aug 2003 | 24 |
| NCT02262559Healthy | 1 | Completed | Aug 2002 | 30 |
| NCT02261129Healthy | 1 | Completed | Dec 2008 | 64 |
| NCT02261116Healthy | 4 | Completed | Aug 2002 | 24 |
| NCT02261064Healthy | 1 | Completed | Feb 2009 | 32 |
| NCT02260089Hypertension | 4 | Completed | Jul 2002 | 134 |
| NCT02259829Healthy | 1 | Completed | Nov 2007 | 84 |
| NCT02259816Healthy | 1 | Completed | Aug 2006 | 38 |
| NCT02259803Healthy | 1 | Completed | Nov 2007 | 30 |
| NCT02259790Healthy | 1 | Completed | Aug 2007 | 30 |
| NCT02242812Hypertension | 4 | Terminated | Oct 2004 | 24 |
| NCT02242370Hypertension | 4 | Completed | Nov 2000 | 3,045 |
| NCT02242344Hypertension | 2 | Completed | Sep 2007 | 77 |
| NCT02242318Hypertension | 4 | Completed | Sep 2002 | 440 |
| NCT02218684Healthy | 1 | Completed | Nov 1998 | 27 |
| NCT02215005Healthy | 1 | Completed | Sep 2007 | 42 |
| NCT02214992Healthy | 1 | Completed | Jun 2007 | 84 |
| NCT02214979Healthy | 1 | Completed | Jun 2007 | 84 |
| NCT02206659Hypertension | 3 | Completed | Feb 2001 | 20 |
| NCT02203500Healthy | 1 | Completed | Jan 1999 | 26 |
| NCT02200653Hypertension | 4 | Completed | Feb 2001 | 387 |
| NCT02200640Hypertension | 4 | Completed | Dec 2000 | 333 |
| NCT02193308Healthy | 1 | Completed | Nov 2007 | 84 |
| NCT02187536Healthy | 1 | Completed | May 2000 | 16 |
| NCT02187523Healthy | 1 | Completed | Dec 1999 | 32 |
| NCT02187497Hypertension | 2 | Completed | Sep 1998 | 93 |
| NCT02187484Hypertension | 2 | Completed | Aug 1999 | 23 |
| NCT02183701Hypertension | 3 | Completed | Dec 1998 | 715 |
| NCT02183675Healthy · Japan | 1 | Completed | Oct 2014 | 36 |
| NCT02178306Hypertension | 4 | Completed | Apr 2002 | 82 |
| NCT02177500Hypertension | 3 | Completed | May 2000 | 327 |
| NCT02177487Hypertension | 3 | Completed | Jan 2000 | 100 |
| NCT02177461Hypertension | 4 | Completed | Aug 2002 | 374 |
| NCT02177448Hypertension | 3 | Completed | Sep 1999 | 225 |
| NCT02177435Hypertension | 3 | Completed | Sep 1999 | 491 |
| NCT02177422Hypertension | 3 | Completed | Nov 1999 | 489 |
| NCT02177409Hypertension | 3 | Completed | Dec 1998 | 431 |
| NCT02177396Hypertension | 3 | Completed | Dec 1998 | 426 |
| NCT02176499Hypertension | 3 | Completed | Jul 1999 | 26 |
| NCT02175355Hypertension | 3 | Completed | Aug 2000 | 1,039 |
| NCT02172586Hypertension | 4 | Completed | Jan 2002 | 363 |
| NCT01344629Healthy · Japan | 1 | Completed | Jul 2011 | 64 |
| NCT01286558Hypertension · Japan | 3 | Completed | Sep 2011 | 225 |
| NCT01278797Hypertension · Canada | 1 | Completed | Feb 2011 | 28 |
| NCT01222520Hypertension · Japan | 3 | Completed | Jun 2011 | 174 |
| NCT01204398Hypertension · China | 3 | Completed | Jul 2011 | 27 |
| NCT01181011Healthy · China | 1 | Completed | Nov 2010 | 28 |
| NCT01134393Hypertension · Germany, Italy, Mexico and more | 3 | Completed | May 2011 | 502 |
| NCT01103960Hypertension · China, Malaysia, Philippines | 3 | Completed | Aug 2011 | 324 |
| NCT00860262Hypertension · United States, Bulgaria, Czech Republic and more | 3 | Completed | Dec 2009 | 858 |
How it is read
Names in the registry
- “Telmisartan”, 38 entries
- “telmisartan”, 7 entries
- “CKD-828, D097, D337”, 6 entries
- “Telmisartan 40 mg”, 6 entries
- “Low dose of telmisartan”, 4 entries
Conditions, from the studies’ own filings
- Hypertension, 77 studies
- Essential Hypertension, 6 studies
- Diabetic Nephropathies, 3 studies
- Hypercholesterolemia, 2 studies
- Hyperlipidemias, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.